<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03149705</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL17_0323</org_study_id>
    <nct_id>NCT03149705</nct_id>
  </id_info>
  <brief_title>Cohort of Ischemic STROKE Patients</brief_title>
  <acronym>HIBISCUSSTROKE</acronym>
  <official_title>CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in Stroke.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ischemic stroke is the first cause of acquired disability of the adult, the second cause of&#xD;
      dementia and the third cause of death in the industrialized countries, what constitutes à&#xD;
      major public health issue. Stroke is characterized by a cerebral parenchymal lesion due to an&#xD;
      ischemic mechanism (85% of the cases) or hemorrhagic mechanism (15%). For a long time, the&#xD;
      only approved treatment was the intravenous thrombolysis (rt-PA). Recently, thrombectomy has&#xD;
      proven its superiority in this pathology.&#xD;
&#xD;
      Cohorts of patients with stroke are rare but can be very valuable by their clinical,&#xD;
      laboratory and imaging well documented. They are the source of new hypotheses for research or&#xD;
      interventions as well as the quality of care assessment tool.&#xD;
&#xD;
      The main objective of this project is to identify new markers: biological and imaging,&#xD;
      treatment response and prognosis after ischemic stroke.&#xD;
&#xD;
      Secondary objectives of the HIBISCUS-STROKE cohort are to establish a clinical database,&#xD;
      completed by biological samples and by imaging data that can be used in the following areas:&#xD;
&#xD;
        -  Descriptive epidemiology of ischemic stroke and cerebral reperfusion,&#xD;
&#xD;
        -  Pharmacoepidemiology and treatments observatory: safety, efficacy, indication of&#xD;
           treatment in real life, costs&#xD;
&#xD;
        -  Assessment of the long-term effect of the treatment on the occurrence of disability,&#xD;
           stroke recurrence and death,&#xD;
&#xD;
        -  Quality of life and personal, familial, professional and social consequences of stroke,&#xD;
&#xD;
        -  Research of new diagnostic and prognostic biomarkers,&#xD;
&#xD;
        -  Research projects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2016</start_date>
  <completion_date type="Anticipated">October 2026</completion_date>
  <primary_completion_date type="Anticipated">October 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of disability (mRS Score)</measure>
    <time_frame>5 years</time_frame>
    <description>Degree of disability: modified Rankin Score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>infarct size</measure>
    <time_frame>day 6</time_frame>
    <description>cerebral infarct size on MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic transformation</measure>
    <time_frame>24 hours</time_frame>
    <description>Hemorrhagic transformation (ECASS scale) on imaging (CT or MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological deficit</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Neurological deficit NIH stroke Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>up to 5 years</time_frame>
    <description>QOL questionnaire</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Ischemic Stroke</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      In usual care of patients admitted for ischemic STROKE at Pierre Wertheimer Hospital, blood&#xD;
      samples were taken on admission in the neurovascular unit (H0), 6h, 24h and 48h after&#xD;
      reperfusion , and during the 3 month clinical visit.&#xD;
&#xD;
      For the constitution of the serum bank of Hibiscus-STROKE cohort, extra tubes are collected&#xD;
      at the same time as the blood tests done routinely.&#xD;
&#xD;
      These additional samples will be centrifuged and treated to form a collection of biological&#xD;
      samples of total serum and plasma and blood stored at the Biological Resource Center of HCL&#xD;
      Neurobiotec at -80 ° C (DC- 2008-72, AC-2013-1867 certified NFS96900 FR13-018140).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Stroke patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt; 18 years&#xD;
&#xD;
          -  Ischemic Stroke confirmed by MRI&#xD;
&#xD;
          -  Proximal arterial occlusion (ICA or M1)&#xD;
&#xD;
          -  Eligible for thrombolysis and/or thrombectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients residing&gt; 50 km from the Pierre Wertheimer Hospital (Lyon, France)&#xD;
&#xD;
          -  Inability to perform the first sample (H0)&#xD;
&#xD;
          -  Patient with progressive or uncontrolled cancer.&#xD;
&#xD;
          -  Refusal to participate in the study or to sign the consent&#xD;
&#xD;
          -  Lack of medical social coverage&#xD;
&#xD;
          -  Deprivation of civil rights&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Norbert NIGHOGHOSSIAN, Prof</last_name>
    <phone>+33 4 72 35 71 70</phone>
    <email>GHE.CICLYON@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathan MEWTON, MD, PhD</last_name>
    <phone>+33 472 357 231</phone>
    <email>GHE.CICLYON@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital neurologique Pierre Wertheimer (Lyon)</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Mewton, MD, PhD</last_name>
      <phone>+33 472 357 231</phone>
      <email>GHE.CICLYON@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 9, 2017</study_first_submitted>
  <study_first_submitted_qc>May 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2017</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemic stroke, stroke, bio-collection, Imaging markers, biomarkers, clinical outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

